# Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

> **NCT06156267** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** mRNA tumor vaccines

## Key facts

- **NCT ID:** NCT06156267
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2026-04
- **Final completion:** 2027-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06156267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06156267, "Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06156267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*